First instrument-based, rapid test uses multi-antigen approach to achieve best-in-class sensitivity and specificity, U.S. FDA EUA submitted.
Genalyte, the company empowering physicians and patients with real-time diagnostics and healthcare analytics, announced today the availability of its rapid COVID-19 serology panel on its Maverick™ platform. The panel tests for the detection of IgG and IgM antibodies that the body produces in response to the novel coronavirus (SARS-CoV-2).